C07C255/30

PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE

The present invention provides processes and key intermediates for the synthesis of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro-propane-2-yl)-1H-pyrazole-4-carboxamide:

##STR00001##

Synthesis of triethylenetetramines

Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.

Synthesis of triethylenetetramines

Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.

SYNTHESIS METHOD APPLIED TO KRAS INHIBITOR DRUG HETEROCYCLIC INTERMEDIATE
20220259150 · 2022-08-18 ·

The present application provides a compound of formula II and a method for preparing a compound of formula I, i.e., 2-iso-propyl-4-methylpyridin-3-amine by using the same. The compound of formula I can be applied to synthesis of KRAS inhibitor drugs. The raw materials involved in the method of the present application are easy to obtain and low in price, operation is easy and convenient, economization and environmental protection are achieved, and industrial production is facilitated.

##STR00001##

SYNTHESIS METHOD APPLIED TO KRAS INHIBITOR DRUG HETEROCYCLIC INTERMEDIATE
20220259150 · 2022-08-18 ·

The present application provides a compound of formula II and a method for preparing a compound of formula I, i.e., 2-iso-propyl-4-methylpyridin-3-amine by using the same. The compound of formula I can be applied to synthesis of KRAS inhibitor drugs. The raw materials involved in the method of the present application are easy to obtain and low in price, operation is easy and convenient, economization and environmental protection are achieved, and industrial production is facilitated.

##STR00001##

Single phase liquids of alkanolamine salts of dicamba

The invention is a herbicidal composition containing an alkanolamine salt of an dicamba capable of remaining as a single phase liquid over a period of at least 1 week and containing low amounts of water and high loadings of the salt. Such herbicidal compositions are capable of remaining liquid in the absence of high amounts of water, thereby enhancing their capacity to remain liquid over an extended period of time when exposed to environmental conditions to improve their effectiveness to transport the active salt through a leafy substrate and can reduce transportation costs by increasing the salt loading without compromising the stability of the composition.

Single phase liquids of alkanolamine salts of dicamba

The invention is a herbicidal composition containing an alkanolamine salt of an dicamba capable of remaining as a single phase liquid over a period of at least 1 week and containing low amounts of water and high loadings of the salt. Such herbicidal compositions are capable of remaining liquid in the absence of high amounts of water, thereby enhancing their capacity to remain liquid over an extended period of time when exposed to environmental conditions to improve their effectiveness to transport the active salt through a leafy substrate and can reduce transportation costs by increasing the salt loading without compromising the stability of the composition.

Isotopically modified compounds and their use as food supplements
10918126 · 2021-02-16 · ·

A nutrient composition comprises an essential nutrient in which at least one exchangeable H atom is .sup.2H and/or at least one C atom is .sup.13C. The nutrient is thus protected from, inter alia, active oxygen species.

Isotopically modified compounds and their use as food supplements
10918126 · 2021-02-16 · ·

A nutrient composition comprises an essential nutrient in which at least one exchangeable H atom is .sup.2H and/or at least one C atom is .sup.13C. The nutrient is thus protected from, inter alia, active oxygen species.

L-PAG DERIVATIVES FOR TREATMENT OF SLEEP DISORDERED BREATHING (SDB)

Described herein are novel - and -propargyl carboxylic acids and esters. The novel compositions are antagonists of CSE and may be used to modulate of the activity of the carotid body, therefore providing therapeutic benefits for sleep-related breathing disorders and related conditions.